Dec 16, 20191 min readChairman Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. JanuaryChairman of the Board, Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January
Chairman of the Board, Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January
Initial iQ-007 IND-Enabling Tox Results Accelerate Prep for First in Human Phase 1 StudyPrinceton, NJ, March 19, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-007, a novel...
iQure Pharma Awarded Its First Patent for iQ-008, a Novel Analgesic Compound to Treat Neuropathic PainPrinceton, NJ, January 23, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-008, a novel...
Comments